Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term zinc histidine hydrate in chronic liver disease with zinc deficiency
jRCT1031250502Not yet recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of zinc histidine hydrate in chronic liver disease (CLD) and zinc deficiency, sponsored by Nobelpharma Co., Ltd. Primary endpoints: Change in serum ammonia levels and Change in blood zinc concentrations. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
zinc histidine hydrate
03
Conditions
chronic liver disease (CLD)zinc deficiency
Beyond the preview
Go deeper on jRCT1031250502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250502.